Senores Pharmaceuticals Limited announced its Q3FY26 results, reporting a consolidated income of ₹175 crores, a significant 64% year-on-year growth. The company's Profit After Tax (PAT) also saw a substantial increase of approximately 85% year-on-year, reaching around ₹32 crores. The growth was broad-based, driven by both regulated and emerging market businesses. Revenue from regulated markets grew by 60.5% YoY to ₹113 crores, attributed to steady product portfolio expansion and scaling of the CDMO-CMO segment. Emerging markets revenue increased by 47.5% YoY to ₹38 crores. India's branded generics business demonstrated exceptional growth, more than tripling its revenue YoY to ₹10.5 crores. Consolidated EBITDA for Q3FY26 stood at ₹54 crores, an 86% YoY increase, with EBITDA margins improving by 360 basis points to 30.9%. For the nine months of FY26, consolidated income reached ₹474 crores, a 65% YoY growth, primarily from the regulated market business. Nine-month EBITDA grew by 87% YoY to ₹138 crores, with margins at 29%. Nine-month PAT more than doubled YoY to ₹84 crores, with PAT margins improving to 17.7%. The company highlighted a strong focus on cash flow generation, with operating cash flow for nine months FY26 at around ₹51 crores. Management expressed confidence in achieving FY26 targets of 50% top-line growth and 100% PAT growth over FY25. The company also announced the acquisition of a 75% stake in Apnar Pharma, a US FDA-approved facility, expected to provide strategic benefits and enhance manufacturing capabilities and flexibility, with the remaining 25% to be completed by Q2 FY'27. Senores Pharmaceuticals Limited's nine-month results are in line with or slightly ahead of annual guidance. The company's ANDAs portfolio has grown significantly, reaching 46 approved ANDAs as of December 2025, covering over 137 product trends. They have 28 approved ANDAs ready for launch and 22 more molecules under development. The CDMO-CMO segment is also scaling up, with a portfolio of 16 commercial products. Management projects branded generics revenue between ₹40-50 crores for FY26 and over ₹80 crores for FY27. Emerging market revenue is projected between ₹170-180 crores for the next year. The company expects to sustain EBITDA margins around 30% for FY26 and anticipates further improvement in FY27.
